(Q44633351)

4 December 2017

title

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine (English)

1 reference

pneumococcal conjugate vaccine

4 December 2017

1 reference

1 reference

1

Elizabeth Miller

1 reference

4 December 2017

3

Pauline A Waight

1 reference

4 December 2017

4

Mary P E Slack

1 reference

4 December 2017

Nicholas J Andrews

2

1 reference

4 December 2017

Robert C George

series ordinal

5

1 reference

4 December 2017

language of work or name

English

0 references

publication date

5 October 2011

1 reference

4 December 2017

1 reference

4 December 2017

volume

29

1 reference

4 December 2017

issue

49

1 reference

4 December 2017

page(s)

9127-9131

1 reference

Serotype replacement in disease after pneumococcal vaccination

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Estimation of vaccine efficacy against acquisition of pneumococcal carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.112

10.1016/J.VACCINE.2011.09.112

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference